MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ctr.13908

Медицинская библиотека · Clinical transplantation · 2020

Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.

Lavacca Antonio, Presta Roberto, Gai Chiara, Mella Alberto, Gallo Ester, Camussi Giovanni, Abbasciano Isabella, Barreca Antonella, Caorsi Cristiana, Fop Fabrizio, Messina Maria, Rossetti Maura, Biancone Luigi

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has been recently used as rescue therapy in patients non-responsive to rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts "per se" or requires a priming effect from previous treatments is currently unknown.

METHODS

Fifteen patients with cAMR were treated with TCZ as a first-line therapy and followed for a median time of 20.7 months.

RESULTS

Despite the majority of patients experiencing advanced transplant glomerulopathy (TG) at diagnosis (60% with cg3), glomerular filtration rate and proteinuria stabilized during the follow-up, with a significant reduction in donor-specific antibodies. Protocol biopsies after 6 months demonstrated significant amelioration of microvascular inflammation and no TG, C4d deposition, or IF/TA progression. Gene-expression and immunofluorescence analysis showed upregulation of three genes (TJP-1, AKR1C3, and CASK) involved in podocyte, mesangial, and tubular restoration.

CONCLUSION

Tocilizumab adopted as a first-line approach in cAMR was associated with early serological and histological improvements and functional stabilization even in advanced TG, suggesting a role for the use of TCZ alone with the avoidance of unnecessary previous immunosuppressants.

Для цитирования: Lavacca Antonio, Presta Roberto, Gai Chiara, Mella Alberto, Gallo Ester, Camussi Giovanni, Abbasciano Isabella, Barreca Antonella, Caorsi Cristiana, Fop Fabrizio, Messina Maria, Rossetti Maura, Biancone Luigi. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.. Clinical transplantation. 2020. DOI: 10.1111/ctr.13908.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.